Bausch Health Cos Inc. (NYSE:BHC) Receives $8.00 Average PT from Analysts

Shares of Bausch Health Cos Inc. (NYSE:BHC) have been given an average rating of “Reduce” by the seven brokerages that are presently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating and five have assigned a hold rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $8.00.

Several research firms have recently commented on BHC. Jefferies Financial Group raised shares of Bausch Health Cos to a “hold” rating in a research report on Wednesday, July 22nd. Weiss Ratings raised shares of Bausch Health Cos from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday. Zacks Research lowered shares of Bausch Health Cos from a “hold” rating to a “strong sell” rating in a research report on Friday, July 24th. Wall Street Zen upgraded shares of Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Finally, Royal Bank Of Canada dropped their price target on shares of Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating on the stock in a research note on Monday, April 27th.

Bausch Health Cos Stock Performance

BHC stock opened at $7.01 on Thursday. The company has a debt-to-equity ratio of 54.68, a current ratio of 1.44 and a quick ratio of 1.08. Bausch Health Cos has a 1 year low of $4.33 and a 1 year high of $8.69. The company has a market cap of $2.62 billion, a P/E ratio of -2.37 and a beta of 0.38. The stock’s fifty day moving average price is $5.02 and its 200-day moving average price is $5.45.

Bausch Health Cos (NYSE:BHC) last posted its quarterly earnings data on Wednesday, July 29th. The company reported $1.26 EPS for the quarter, beating analysts’ consensus estimates of $0.96 by $0.30. Bausch Health Cos had a negative return on equity of 561.95% and a negative net margin of 10.12%.The company had revenue of $2.83 billion during the quarter, compared to analysts’ expectations of $2.59 billion. On average, equities analysts forecast that Bausch Health Cos will post 4.05 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Frank D. Lee sold 24,456 shares of Bausch Health Cos stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $5.43, for a total transaction of $132,796.08. Following the transaction, the director directly owned 49,339 shares in the company, valued at approximately $267,910.77. The trade was a 33.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 20.67% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Caption Management LLC increased its holdings in Bausch Health Cos by 101.1% in the 4th quarter. Caption Management LLC now owns 4,464 shares of the company’s stock worth $31,000 after acquiring an additional 405,789 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its position in shares of Bausch Health Cos by 12,589.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 4,949 shares of the company’s stock worth $34,000 after purchasing an additional 4,910 shares during the period. Northwestern Mutual Wealth Management Co. increased its stake in shares of Bausch Health Cos by 6,661.2% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 5,409 shares of the company’s stock worth $35,000 after purchasing an additional 5,329 shares in the last quarter. Russell Investments Group Ltd. raised its position in shares of Bausch Health Cos by 65.9% during the 2nd quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock valued at $51,000 after purchasing an additional 3,106 shares during the period. Finally, Camelot Portfolios LLC purchased a new position in shares of Bausch Health Cos during the 4th quarter valued at $59,000. Institutional investors own 78.65% of the company’s stock.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.